Abstract
Background Electrocardiographic (ECG) Heart Age conveying cardiovascular risk has been estimated by both Bayesian and artificial intelligence approaches. We hypothesized that explainable measures from the 10-second 12-lead ECG could successfully predict Bayesian ECG Heart Age.
Methods Advanced analysis was performed on ECGs from healthy subjects and patients with cardiovascular risk or proven heart disease. Regression models were used to predict a Bayesian 5-minute ECG Heart Age from the standard resting 10-second 12-lead ECG. The difference between 10-second ECG Heart Age and chronological age was compared.
Results In total, 2,771 subjects were included (n=1682 healthy volunteers, n=305 with cardiovascular risk factors, n=784 with cardiovascular disease). Overall, 10-second Heart Age showed strong agreement with the 5-minute Heart Age (R2=0.94, p<0.001, mean±SD bias 0.0±5.1 years). The difference between 10-second ECG Heart Age and chronological age was 0.0±5.7 years in healthy individuals, 7.4±7.3 years in subjects with cardiovascular risk factors (p<0.001), and 14.3±9.2 years for patients with cardiovascular disease (p<0.001).
Conclusions ECG Heart Age can be accurately estimated from a 10-second 12-lead ECG in a transparent and explainable fashion based on known ECG measures, without artificial intelligence techniques. The difference between ECG Heart Age and chronological age increases markedly with cardiovascular risk and disease.
Competing Interest Statement
TTS is owner and founder of Nicollier-Schlegel SARL, which performs ECG interpretation consultancy using software that can quantify the advanced ECG measures used in the current study. TTS and MU are owners and founders of Advanced ECG Systems, a company that is developing commercial applications of advanced ECG technology used in the current study.
Funding Statement
TL is currently under the support of postdoctoral research grants from The Swedish Heart-Lung Foundation (grant no 20200553), the Swedish Cardiac Society, the Royal Swedish Academy of Sciences (grant no LM2019-0013), Women and Health Foundation, Region Kronoberg (grant no 8301), The Swedish Heart and Lung Association (grant no LKH1387), Swedish Association of Clinical Physiology, and the Scandinavian Society of Clinical Physiology; Nuclear Medicine. The study was funded in part by grants (PI Ugander) from New South Wales Health, Heart Research Australia, and the University of Sydney.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All recordings were obtained under Institutional Review Board (IRB) approvals from NASA's Johnson Space Center and partner hospitals that fall under IRB exemptions for previously collected and de-identified data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Fundings: TL is currently under the support of postdoctoral research grants from The Swedish Heart-Lung Foundation (grant no 20200553), the Swedish Cardiac Society, the Royal Swedish Academy of Sciences (grant no LM2019-0013), Women and Health Foundation, Region Kronoberg (grant no 8301), The Swedish Heart and Lung Association (grant no LKH1387), Swedish Association of Clinical Physiology, and the Scandinavian Society of Clinical Physiology; Nuclear Medicine. The study was funded in part by grants (PI Ugander) from New South Wales Health, Heart Research Australia, and the University of Sydney.
Competing interests: TL, IPL: None TTS is owner and founder of Nicollier-Schlegel SARL, which performs ECG interpretation consultancy using software that can quantify the advanced ECG measures used in the current study. TTS and MU are owners and founders of Advanced ECG Systems, a company that is developing commercial applications of advanced ECG technology used in the current study.
Data Availability
All data utilized in the present study are available upon reasonable request to the authors.
